11/07/2025 Cel-Sci to partner with a leading Saudi Arabian pharma company for Multikine in the Tx of Head & Neck Cancer (Ref) Cel-Sci Corporation announced an agreement with one of Saudi Arabia’s premier pharmaceutical and healthcare companies for a partnership that spans regulatory and commercial activities for Multikine (Leukocyte Interleukin, Injection) in the Kingdom of Saudia Arabia The Saudi pharmaceutical partner which will file a Breakthrough Medicine Designation appl

01/07/2025 HanchorBio and Henlius signed a ~$200M licensing deal for HanchorBio's HCB101 (Ref) HanchorBio and Shanghai Henlius Biotech signed an out-licensing agreement which granted Henlius the exclusive development and commercialization rights to HanchorBio's HCB101 (SIRPα-IgG4 Fc fusion protein) across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle East and North Africa (MENA) Under the